Barclays PLC Buys 129,944 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

Barclays PLC lifted its position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 139.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 222,919 shares of the company's stock after acquiring an additional 129,944 shares during the quarter. Barclays PLC owned approximately 0.26% of Verve Therapeutics worth $1,079,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the company. State Street Corp lifted its position in shares of Verve Therapeutics by 27.0% during the third quarter. State Street Corp now owns 4,253,217 shares of the company's stock worth $20,586,000 after acquiring an additional 903,809 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its stake in shares of Verve Therapeutics by 72.2% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,559,393 shares of the company's stock valued at $7,547,000 after purchasing an additional 653,578 shares during the period. Braidwell LP purchased a new stake in Verve Therapeutics during the 3rd quarter worth about $3,020,000. Novo Holdings A S boosted its stake in Verve Therapeutics by 20.0% in the 2nd quarter. Novo Holdings A S now owns 2,400,000 shares of the company's stock worth $11,712,000 after purchasing an additional 400,000 shares during the period. Finally, Cubist Systematic Strategies LLC boosted its stake in Verve Therapeutics by 245.5% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 395,699 shares of the company's stock worth $1,931,000 after purchasing an additional 281,173 shares during the period. Hedge funds and other institutional investors own 97.11% of the company's stock.

Verve Therapeutics Price Performance

NASDAQ VERV opened at $5.37 on Wednesday. The business's 50-day moving average is $5.83 and its 200 day moving average is $5.74. The stock has a market capitalization of $454.65 million, a PE ratio of -2.18 and a beta of 1.68. Verve Therapeutics, Inc. has a 1 year low of $4.30 and a 1 year high of $19.34.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.70) by $0.11. The business had revenue of $6.87 million during the quarter, compared to analyst estimates of $2.75 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. Verve Therapeutics's quarterly revenue was up 120.2% compared to the same quarter last year. During the same period last year, the business posted ($0.72) earnings per share. As a group, equities research analysts anticipate that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

VERV has been the subject of several recent analyst reports. Canaccord Genuity Group boosted their price objective on shares of Verve Therapeutics from $29.00 to $32.00 and gave the company a "buy" rating in a research note on Wednesday, November 6th. Royal Bank of Canada lowered their price objective on shares of Verve Therapeutics from $20.00 to $17.00 and set an "outperform" rating on the stock in a research report on Wednesday, November 6th. Finally, HC Wainwright cut their target price on shares of Verve Therapeutics from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Wednesday, November 6th.

Verve Therapeutics Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.